Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- New Price Cut Rule for Long-Listed Products Blow to Drug Makers
January 6, 2014
- Azilva Tops SOC Ranking for Second Month in a Row in November in Both Hospital and GP Markets: Anterio
January 6, 2014
- Novartis Seeks Japanese Regulatory Approval of Psoriasis Agent Secukinumab
January 6, 2014
- Shionogi, AZ Revise Royalty Rate for Crestor
January 6, 2014
- Takeda to End Development of TAK-875 Due to Liver Safety Concerns
December 27, 2013
- Nissan Chemical Sues Seven Generic Companies over Livalo Patents
December 27, 2013
- Ono Files NDA for Nivolumab for Malignant Melanoma
December 27, 2013
- MSD Files NDA for Vaniprevir for Chronic Hepatitis C
December 27, 2013
- Kissei Grants US Pfizer Worldwide Exclusive Rights for Gout and Hyperuricemia Treatment KUX-1151 Outside Japan
December 26, 2013
- Meiji Seika Pharma Scraps Codevelopment Deal with Danish Biotech
December 26, 2013
- Takeda to License Inflammatory Bowel Disease Treatment from US Biotech
December 25, 2013
- Tenelia Now Indicated for Type 2 Diabetes Without Concurrent Use Restrictions
December 25, 2013
- SSI Said Ex-Employee Manipulated Data of Anti-Obesity Drug Study
December 25, 2013
- Daiichi Sankyo Files Edoxaban for AF, VTE New Indications
December 25, 2013
- Kyowa Kirin, LEO Pharma Collaborate to Market Fixed-Dose Combination Topical Treatment for Psoriasis in Japan
December 24, 2013
- Shire Names NBI Operating Officer Sunohara as New Japan Head
December 20, 2013
- Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
- Can Epadel Continue to Maintain Sales in the Face of Competition from Lotriga and Generics?
December 20, 2013
- UMN, API, Yakult Conclude Another Joint Biosimilar Business Agreement in Oncology Field
December 19, 2013
- Astellas, Nichi-Iko Conclude Definitive Agreement on Transfer of Fuji Plant
December 19, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…